Pharmafile Logo
Pharmafocus logo
Advanced Search

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020
Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …

News
nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

News
shutterstock

Gilead’s remdesivir and three other repurposed drugs have no impact on COVID-19 mortality, WHO study finds

October 16, 2020
Medical Communications, Research and Development COVID-19, pharma, remdesivir

Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections, but recent studies …

News
the_stethoscope_peru

Five-year-old girl that was part of Lysogene’s gene therapy clinical trial dies

October 16, 2020
Medical Communications

A five-year-old girl had died while taking part in Lysogene’s clinical trial investigating its gene therapy. The child was suffering …

News
covid_cell_1

‘Long COVID’ could be taking four different forms

October 16, 2020
Medical Communications coronavirus, covid symptoms, long covid, symptoms

People experiencing chronic illnesses after COVID-19 infections could be suffering from one of four separate conditions, according to new research. …

News
top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

October 16, 2020
Medical Communications COVID, herd immunity, top ten, top ten articles

The top ten news stories this week focus on herd immunity, as the Director of the World Health Organization has …

News
piccadilly_circus_station_during_london_covid-19_lockdown

80 researchers argue COVID-19 herd immunity strategy is a “dangerous fallacy” in open letter

October 15, 2020
Medical Communications, Research and Development, Sales and Marketing COVID-19

A group of 80 researchers have lent their signatures to an open letter published in the The Lancet under the …

News

Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis

October 15, 2020
Sales and Marketing Mayzent, Novartis, Scotland

Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …

News

NICE recommends siponimod for treating secondary progressive MS

October 15, 2020
Medical Communications

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending siponimod for treating secondary progressive multiple …

News
800px-who_in_ppe

FDA approves Regeneron’s antibody Ebola treatment

October 15, 2020
Research and Development Ebola, ebola antibody., ebola treatment

The FDA has approved Regeneron’s antibody drug inmazeb for treating Ebola. The treatment works through targeting the glycoprotein on the …

News
800px-roberto_fico_in_the_russian_state_duma_2019-03-05_03

Russia gives regulatory approval to second COVID-19 vaccine after early clinical trials

October 15, 2020
Research and Development COVID Vaccine, Vaccine, coronavirus vaccine

Russian President Vladimir Putin announced on Wednesday that regulators had given approval to a second coronavirus vaccine. This new vaccine …

News
450px-flag_of_scotland

Scottish Medicines Consortium approves Revlimid for two groups of blood cancer patients

October 14, 2020
Research and Development Revlimid, SMC

The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland for patients with multiple myeloma …

News
800px-eli_lilly_corporate_center_indianapolis_indiana_usa_1

Eli Lilly COVID-19 antibody therapy trial paused over safety concerns

October 14, 2020
Research and Development COVID, Eli Lilly, coronavirus

Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns.  …

News
pxfuel

British man suffers from permanent hearing damage after contracting COVID-19

October 14, 2020
Research and Development COVID-19, pharma

A 45-year-old man in the UK has been left with permanent hearing damage after being infected with the novel coronavirus, …

News
shutterstock_512649

Johnson & Johnson to contribute a further $1 billion to US opioid settlement

October 14, 2020
Research and Development, Sales and Marketing J&J, JJ, opioid crisis, opioids, pharma

Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the opioid crisis in the US. …

News
covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

October 14, 2020
Research and Development COVID-19, coronavirus, covid news, pandemic, weekly roundup

The COVID-19 news this week focuses on FDA authorisations, with Eli Lilly seeking Emergency Use Authorization (EUA) from the FDA …

News
800px-healthcare_workers_wearing_ppe_03_2

Man in US contracts COVID-19 for the second time with worse symptoms

October 13, 2020
Manufacturing and Production COVID, coronavirus

An American man has caught coronavirus for the second time, with the second infection being far more dangerous than the …

News

J&J halts COVID-19 vaccine study following unidentified participant illness

October 13, 2020
Manufacturing and Production, Research and Development COVID-19, J&J, JJ, Vaccine, pharma

Johnson & Johnson has announced its decision to slam the brakes on the development programme for its COVID-19 vaccine following …

News
800px-who_flag

Head of WHO says herd immunity strategies for COVID-19 are ‘unethical’

October 13, 2020
Manufacturing and Production

Tedros Adhanom Ghebreyesus, Director of the World Health Organization, has warned against pursuing a strategy of herd immunity to fight …

News
bavencio

Bavencio/axitinib combo approved for NHS Scotland in advanced renal cell carcinoma

October 13, 2020
Manufacturing and Production, Sales and Marketing Merck, NHS, Pfizer, SMC

The Scottish Medicines Consortium (SMC) has given the go-ahead to Merck KGaA and Pfizer’s combination of their PD-L1 inhibitor immunotherapy …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025